diabetes

diabetes

Diabetes, Endocrinology and Metabolism Group

The Academic Diabetes, Endocrinology and Metabolism Research Group (ADEM) is a team of clinical and academic researchers, led by Professor Thozhukat Sathyapalan, with expertise in diabetes, obesity, cardiovascular disease, exercise, dietetics, biochemistry, psychology and sociology.

ADEM delivers world-class research in four areas: clinical drugs trials; lifestyle research; biomedical research; and applied research. ADEM’s research findings have benefited those suffering from long-term conditions and led to significant advancement in treatment and medical knowledge. The group specialises in type 1 and 2 diabetes, metabolic syndrome, obesity, polycystic ovary syndrome, insulin resistance, non-alcoholic fatty liver disease, metabolic bone health, cardiovascular disease, and dietetics and nutrition. 

The group, which is a partnership between the Hull York Medical School and the University of Hull, is situated at Hull Royal Infirmary and the university campus. Aside from research, it also provides a range of outstanding academic postgraduate pathways and educational opportunities, including PhDs, MDs and MScs.  

ADEM’s excellent research facilities include body imaging and DEXA scanning to measures bone mineral density, dedicated laboratories, a sports science laboratory, ultrasound and access to a large pool of patients.

Members

Head of Group


Unit Manager

  • Lisa Baldwin


Academic and research staff

  • Dr Mo Aye – Consultant Endocrinologist, Honorary Senior Lecturer
  • Dr Ahmed Al-Qaissi - Clinical Research Fellow
  • Mr James England – Consultant Endocrine Surgeon (Thyroid/parathyroid)
  • Dr David Hepburn – Clinical Dean, Hull and East Yorkshire Hospitals NHS Trust and Honorary Reader in Diabetes, Endocrinology and Metabolism
  • Dr Zeeshan Javed – Clinical Research Fellow
  • Dr Maria Papageorgiou – Advanced Research Dietician
  • Mrs Liz Wells - Advanced Research Dietician
  • Dr Sam Xu – Reader in Diabetes, Endocrinology and Metabolism


Collaborators

  • Dr Kamrudeen Mohammed – Consultant Endocrinologist, Honorary Senior Lecturer
  • Dr Shiva Mongolu – Consultant Endocrinologist – Honorary Lecturer


Professional support staff

  • Gill Byne – PA to Professor Sathyapalan
  • Donna Jacklin –  Laboratory Assistant
  • Anneli James – Research Practitioner/Project Manager
  • Dawn Lowsley – Clinical Trials Assistant
  • Lucy Newton – Clinical trials coordinator
  • Lee Rollins – Research Practitioner
  • Dana Schofield – Research Administrator
  • Zoe Sugden – Health Care Assistant
  • Carrie Willby – Clinical Trials Assistant

 

Studies
PATRO

Disease area: Growth hormone deficiancy
Funder: SANDOZ

Post-Marketing Surveillance to monitor the long-term safety and efficacy of Omnitrope in the treatment of children and adults. PATROa (adults) PATROc (children).

Trialnet

Disease area: Type 1 diabetes
Funder: National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes research Foundation and the American Diabetes Association

Natural History Study of the Development of Type 1 Diabetes. Phase 1,2 and 3.

The Prevalence of Acromegaly in the Sleep Apnoea Clinic (ACROS)

Disease area: Endocrine disorders
Funder: Leeds Teaching Hospitals Trust

To assess the prevalence of undiagnosed acromegaly in the sleep apnoea clinic compared to an unselected population 

DUAL 8

Disease area: Type 2 diabetes
Funder: Novo Nordisk

A 104-week, multi-centre, multinational, open-label, two-arm parallel, randomised to insulin degludec/liraglutide (IDegLira) vs.insulin glargine therapy in subjects with T2DM inadequately controlled on OAD(s)

Rewind

Diease area: Type 2 diabetes
Funder: Eli Lilly and Company

The Effect of LY2189265 on Major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)

Reversing PCOS

Diease area: Polycystic ovary syndrome
Funder: Hull and East Yorkshire Hospitals NHS Trust, and partially supported by Cambridge Weight company

A randomised controlled trial to investigate the effect of very low calorie diet (VLCD) versus an energy deficit approach weight loss diet, over 8 weeks, in obese women with polycystic ovarian syndrome (PCOS).

Clear Harmony

Diease area: Hypercholesterolemia
Funder: Esperion Therapeutics

A multicentre  open – lable extension (OLE) study to assess the long term safety and efficacy of Bempedoic Acid (ETC-1002) 180 MG

Pioneer 5

Diease area: Type 2 diabetes and moderate renal impairment
Funder: Novo Nordisk

Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment

REAL 1

Diease area: Growth hormone deficiency
Funder: Novo Nordisk

A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin® FlexPro® in adults with growth hormone deficiency for 35 weeks, with a 53-week extension period.

Acro MultiJoint

Disease area: Acromegaly
Funder: Leeds Teaching Hospitals NHS Trust and Pfizer Inc.

Characterisation of the impact of joint disease on patients with acromegaly

LIBERATES

Disease area: Type 2 diabetes
Funder: National institute for Health research for patient benefit (RfPB)

Improving glucose control in patients with Diabetes following myocardial infarction: the role of a novel glycaemia monitoring strategy. 

Real world Alirocumab Use in the UK

Disease area: Hypercholesterolaemia
Funder: Sanofi

A retrospective observational study to determine the baseline characteristics and treatment patterns of patients taking alirocumab in the UK

Service Users’ perspectives on accessing type 2 diabetes services 

Disease area: Type 2 diabetes
Funder: Hull and East Yorkshire Hospitals NHS Trust and East Riding of Yorkshire CCG

Mixed methods study assessing Service Users' Perspectives on Accessing Type 2 Diabetes Mellitus Services within Hull the East Riding of Yorkshire and North East Lincolnshire and Goole

Empaglifolzin vs Metformin in PCOS (EMMET)

Diease area: polycystic ovary syndrome
Funder: Hull and East Yorkshire Hospitals NHS Trust

The effect of empagliflozin versus metformin on hormonal, metabolic and cardiovascular risk factors in patients with polycystic ovary syndrome (PCOS) – a randomised open-label parallel study.